|
Jul 24
|
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
|
|
Jul 23
|
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
|
|
Jun 29
|
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
|
|
Jun 25
|
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
|
|
Jun 24
|
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
|
|
Jun 13
|
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
|
|
Jun 9
|
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
|
|
May 17
|
Strong week for OPKO Health (NASDAQ:OPK) shareholders doesn't alleviate pain of three-year loss
|
|
May 15
|
OPKO Health to Participate in Two Upcoming Investor Conferences
|
|
Apr 17
|
OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025
|
|
Apr 16
|
OPKO Health, Inc. (NASDAQ:OPK) boasts of bullish insider sentiment with 52% ownership and they have been buying lately
|
|
Mar 14
|
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More.
|
|
Mar 14
|
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now?
|
|
Mar 14
|
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
|
|
Mar 12
|
Labcorp to acquire certain assets of Opko Health’s BioReference Health
|
|
Mar 12
|
Truist remains bullish on Labcorp after ‘another nice strategic acquisition’
|
|
Mar 11
|
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
|
|
Feb 13
|
OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
|
|
Feb 12
|
Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy?
|
|
Oct 7
|
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
|